Forest Devices this week touted study results for its AlphaStroke technology for identifying patients with large vessel occlusive (LVO) strokes.
Pittsburgh-based Forest Devices, one of MassDevice’s 2020 medical device startups you need to know, designed the AlphaStroke platform to detect stroke and LVO, offering first responders the ability to use the system to triage patients so that they go to the right hospital.
In the EDGAR study, which had its results published in the American Heart Association Journal, STROKE, AlphaStroke was 28% to 40% superior compared to clinical exams currently used by medics to make triage decisions when it came to correctly identifying patients with LVO.
Additionally, AlphaStroke proved to be equally as effective as the clinical exams in correctly ruling out patients with non-LVO diagnoses, according to a news release.
“The results from the EDGAR study are a high-water mark in the global effort to improve early identification of patients needing thrombectomy,” Forest Devices CEO Matt Kesinger said in the release. “As a former EMT on ambulances, I experienced the challenge of correctly identifying stroke patients with only a few clinical exam questions. The EDGAR study is the first study, in which a portable technology, designed specifically for LVO identification, has been shown to outperform clinical exams currently applied by EMT’s worldwide.”
